AbbVie Inc. (NYSE:ABBV - Get Free Report) declared a quarterly dividend on Friday, February 14th,Wall Street Journal reports. Shareholders of record on Tuesday, April 15th will be given a dividend of 1.64 per share on Thursday, May 15th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.40%. The ex-dividend date of this dividend is Tuesday, April 15th.
AbbVie has increased its dividend payment by an average of 6.0% per year over the last three years. AbbVie has a dividend payout ratio of 47.1% indicating that its dividend is sufficiently covered by earnings. Research analysts expect AbbVie to earn $13.96 per share next year, which means the company should continue to be able to cover its $6.56 annual dividend with an expected future payout ratio of 47.0%.
Shares of NYSE ABBV traded down $0.45 during midday trading on Friday, reaching $193.00. The company had a trading volume of 3,968,891 shares, compared to its average volume of 5,889,024. The company has a current ratio of 0.65, a quick ratio of 0.54 and a debt-to-equity ratio of 9.64. The business's 50-day simple moving average is $178.59 and its 200 day simple moving average is $185.96. AbbVie has a 1 year low of $153.58 and a 1 year high of $207.32. The stock has a market cap of $341.05 billion, a P/E ratio of 80.42, a P/E/G ratio of 1.53 and a beta of 0.58.
AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a return on equity of 257.91% and a net margin of 7.59%. During the same quarter in the previous year, the firm posted $2.79 EPS. On average, analysts forecast that AbbVie will post 12.32 earnings per share for the current fiscal year.
In other news, SVP Kevin K. Buckbee sold 1,800 shares of the business's stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $172.24, for a total value of $310,032.00. Following the sale, the senior vice president now directly owns 6,983 shares of the company's stock, valued at approximately $1,202,751.92. The trade was a 20.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.25% of the stock is currently owned by company insiders.
Several brokerages recently issued reports on ABBV. Piper Sandler Companies reissued an "overweight" rating and set a $220.00 target price on shares of AbbVie in a report on Tuesday, December 17th. UBS Group raised their price target on shares of AbbVie from $181.00 to $190.00 and gave the company a "neutral" rating in a research report on Monday, February 3rd. Wolfe Research assumed coverage on shares of AbbVie in a research report on Friday, November 15th. They set an "outperform" rating and a $205.00 price target on the stock. Citigroup raised their price target on shares of AbbVie from $205.00 to $215.00 and gave the company a "buy" rating in a research report on Monday, February 3rd. Finally, Sanford C. Bernstein assumed coverage on shares of AbbVie in a research report on Thursday, October 17th. They set a "market perform" rating and a $203.00 price target on the stock. Five research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, AbbVie has an average rating of "Moderate Buy" and an average price target of $208.35.
Check Out Our Latest Report on AbbVie
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.